Le Xi, Zhang Yin, Yang Mei, Li Jie, Wang Hao, Wu Jin-Lin, Deng Juan, Zhang Hong-Min
Department of Endocrinology, People's Hospital of Chongqing Liang Jiang New Area, Chongqing 400000, China.
The Key Laboratory of Laboratory Medical Diagnostics in the Ministry of Education and Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing Medical University, Chongqing 400000, China.
World J Gastroenterol. 2024 Dec 7;30(45):4791-4800. doi: 10.3748/wjg.v30.i45.4791.
Nonalcoholic fatty liver disease (NAFLD) encompasses a variety of liver conditions impacting individuals who consume minimal or no alcohol. Recently, traditional Chinese medicine has been gradually used to treat mild to moderate fatty liver, among which Lindl. powder has been affirmed by many doctors and patients to be effective. However, there is limited research on combining this treatment with standard therapies for mild to moderate NAFLD.
To survey the effect of combining Lindl. powder with standard treatment on liver function and lipid metabolism disorder in patients with mild to moderate NAFLD.
Eighty patients with mild to moderate NAFLD participated in this retrospective study, classified into two groups: The observation group ( = 40) and the control group ( = 40). In November 2020 and November 2022, the study was conducted at People's Hospital of Chongqing Liang Jiang New Area. The control group received standard treatment, while the observation group received Lindl. powder based on the control group. The study compared differences in traditional Chinese medicine clinical syndrome scores, liver fibrosis treatment, liver function indicators, lipid levels, and serum inflammatory factor levels before and after treatment, and we calculated the incidence of adverse reactions for both groups.
The total effective rate was 97.50% in the observation group and 72.5% in the control group. After 8 weeks of treatment, the main and secondary symptom scores remarkably decreased, especially in the observation group ( < 0.05), and there was a significant reduction in the serum levels of hyaluronic acid (HA), laminin (LN), human rocollagen III (PC III), and collagen type IV (CIV). The levels of HA, LN, PC III, and CIV were significantly lower in the observation group ( < 0.05). After 8 weeks, both groups indicated remarkable improvements in liver function and blood lipid levels, with the observation group having even lower levels ( < 0.05). Serum levels of interleukin-1β, tumor necrosis factor-α, and interleukin-8 also dropped significantly. The observation group had a lower rate of adverse reactions (5.00%) compared to the control group (22.50%).
Adding Lindl. powder to standard treatment has been found to remarkably improve symptoms and reduce inflammation in patients with mild to moderate fatty liver disease. It also enhances hepatic function and lipid profile, ameliorates liver fibrosis indices, and lowers the risk of side effects. Consequently, this therapeutic protocol shows promise for clinical implementation and dissemination.
非酒精性脂肪性肝病（NAFLD）涵盖了多种影响极少饮酒或不饮酒个体的肝脏疾病。近年来，中医逐渐被用于治疗轻至中度脂肪肝，其中 散已被众多医生和患者证实有效。然而，关于将这种疗法与轻至中度NAFLD的标准疗法联合应用的研究较少。
探讨 散联合标准治疗对轻至中度NAFLD患者肝功能及脂质代谢紊乱的影响。
80例轻至中度NAFLD患者参与了这项回顾性研究，分为两组：观察组（ = 40）和对照组（ = 40）。2020年11月至2022年11月，该研究在重庆两江新区人民医院进行。对照组接受标准治疗，观察组在对照组基础上加用 散。研究比较了治疗前后中医临床证候评分、肝纤维化指标、肝功能指标、血脂水平和血清炎症因子水平的差异，并计算了两组的不良反应发生率。
观察组总有效率为97.50%，对照组为72.5%。治疗8周后，主要和次要症状评分显著降低，尤其是观察组（ < 0.05），血清透明质酸（HA）、层粘连蛋白（LN）、人Ⅲ型前胶原（PCⅢ）和Ⅳ型胶原（CIV）水平显著降低。观察组HA、LN、PCⅢ和CIV水平显著更低（ < 0.05）。8周后，两组肝功能和血脂水平均显著改善，观察组更低（ < 0.05）。血清白细胞介素-1β、肿瘤坏死因子-α和白细胞介素-8水平也显著下降。观察组不良反应发生率（5.00%）低于对照组（22.50%）。
在标准治疗基础上加用 散可显著改善轻至中度脂肪肝患者的症状，减轻炎症。还可增强肝功能和脂质状况，改善肝纤维化指标，并降低副作用风险。因此，该治疗方案具有临床应用和推广的前景。
